⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193153 | 0.94 | — | — | |
| SCHEMBL17041910 | 0.92 | CYP1A2 (0.48) | — | |
| SCHEMBL26069 | 0.92 | EPHX1 (0.50) | — | |
| Ammonia Solution, Strong SCHEMBL28003292 | 0.92 | CYP1A2 (0.48) | — | |
| SCHEMBL24115531 | 0.92 | EPHX1 (0.50) | — | |
| SCHEMBL23348055 | 0.92 | EPHX1 (0.50) | — | |
| Hydrochloric Acid SCHEMBL7027756 | 0.92 | CYP1A2 (0.48) | — | |
| SCHEMBL3140310 | 0.92 | EPHX1 (0.50) | — | |
| SCHEMBL3686292 | 0.92 | EPHX1 (0.50) | — | |
| SCHEMBL13964480 | 0.92 | EPHX1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4293016-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| CN-115109036-A | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-09-27 | — | — | CN | claimed |
| WO-2022194265-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | 北京赛特明强医药科技有限公司 | 2022-09-22 | — | — | WO | claimed |
| CN-115109036-B | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4107198-B1 | POLYISOCYANATE PREPARATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4293016-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| EP-3560975-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| EP-3724251-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023104209-A1 | METTL3 INHIBITOR COMPOUND | 上海昂阔医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-3851472-B1 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-6413979-B1 | ANTAGONISTS TO ENDOTHELINS; VASODILATORS AND BRONCHODILATORS; SYNTHESIS ROUTES; HYPERTENSION, ASTHMA, RAYNAUD'S DISEASE, RENAL AND HEART FAILURE, ANGINA, DIABETES, CEREBRAL INFARC-TION AND VASOSPASM, ARTERIOSCLEROSIS, RESTENOSIS, PROSTATISM | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6380195-B1 | INCLUDING (METHYLENEDIOXYPHENYL)CYCLOPENTENO(1,2-B)PYRIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| US-6197970-B1 | REACTING WITH SECONDARY OR TERTIARY AMINE; DEBLOCKING, DEPROTECTING | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0714897-B1 | FUSED HETEROAROMATIC CYCLOPENTENE DERIVATIVE HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | BANYU PHARMA CO LTD (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-6087360-A | TREATING PATIENTS WITH ENDOTHELIN RELATED DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-5834483-A | Method of treating heart failure with endothelin antagonists | MERCK & CO., INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5714479-A | TREATMENT OF HYPERTENSION, ACUTE RENAL FAILURE, ANGINA PECTORIS, ARTERIOSCLEROSIS, ASTHMA, GASTRIC ULCER AND SIMILAR AILMENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-03 | — | — | US | disclosed |
| EP-0714897-A1 | FUSED HETEROAROMATIC CYCLOPENTENE DERIVATIVE HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |